Sökning: onr:"swepub:oai:gup.ub.gu.se/290104" > Cognitive Outcomes ...
Fältnamn | Indikatorer | Metadata |
---|---|---|
000 | 07180naa a2201213 4500 | |
001 | oai:gup.ub.gu.se/290104 | |
003 | SwePub | |
008 | 240910s2020 | |||||||||||000 ||eng| | |
024 | 7 | a https://gup.ub.gu.se/publication/2901042 URI |
024 | 7 | a https://doi.org/10.1016/j.jamda.2019.08.0062 DOI |
040 | a (SwePub)gu | |
041 | a eng | |
042 | 9 SwePub | |
072 | 7 | a ref2 swepub-contenttype |
072 | 7 | a art2 swepub-publicationtype |
100 | 1 | a Dyer, A. H.4 aut |
245 | 1 0 | a Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD |
264 | 1 | b Elsevier BV,c 2020 |
520 | a Objective: Benzodiazepines and related drugs (BDZRs) have been associated with an increased risk of Alzheimer's disease (AD) in later life. Despite this, it remains unclear whether ongoing BDZR use may further accelerate cognitive decline in those diagnosed with mild to moderate AD. Design: This study was embedded within NILVAD, a randomized controlled trial of nilvadipine in mild to moderate AD. Cognition was measured at baseline and 18 months using the Alzheimer Disease Assessment Scale, Cognitive Subsection (ADAS-Cog). We assessed predictors of long-term BDZR use and analyzed the effect of ongoing BDZR use on ADAS-Cog scores at 18 months. Additionally, the impact of BDZR use on adverse events, incident delirium, and falls over 18-month follow-up was assessed adjusting for relevant covariates. Setting and Participants: 448 participants with mild to moderate AD recruited from 23 academic centers in 9 European countries. Results: Overall, 14% (62/448) were prescribed an ongoing BDZR for the study duration. Increasing total number of (non-BDZR) medications was associated with a greater likelihood of BDZR prescription (odds ratio 1.16, 95% confidence interval 1.05-1.29). At 18 months, BDZR use was not associated with greater cognitive decline on the ADAS-Cog controlling for baseline ADAS-Cog scores, age, gender, study arm, and other clinical covariates (beta = 1.62, -1.34 to 4.56). However, ongoing BDZR use was associated with a greater likelihood of adverse events [incidence rate ratio (IRR) 1.19, 1.05-1.34], incident delirium (IRR 2.31, 1.45-3.68), and falls (IRR 1.66, 1.02-2.65) over 18 months that persisted after robust adjustment for covariates. Conclusions and Implications: This study found no effect of ongoing BDZR use on ADAS-Cog scores in those with mild to moderate AD over 18 months. However, ongoing use of these medications was associated with an increased risk of adverse events, delirium, and falls. Thus, BDZR use should be avoided where possible and deprescribing interventions should be encouraged in older adults with AD. (C) 2019 AMDA - The Society for Post-Acute and Long-Term Care Medicine. | |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Geriatrik0 (SwePub)302222 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Geriatrics0 (SwePub)302222 hsv//eng |
650 | 7 | a MEDICIN OCH HÄLSOVETENSKAPx Medicinska och farmaceutiska grundvetenskaperx Neurovetenskaper0 (SwePub)301052 hsv//swe |
650 | 7 | a MEDICAL AND HEALTH SCIENCESx Basic Medicinex Neurosciences0 (SwePub)301052 hsv//eng |
653 | a Dementia | |
653 | a benzodiazepines | |
653 | a cognition | |
653 | a benzodiazepines and related drugs | |
653 | a older-adults | |
653 | a risk | |
653 | a dementia | |
653 | a delirium | |
653 | a decline | |
653 | a Geriatrics & Gerontology | |
700 | 1 | a Murphy, C.4 aut |
700 | 1 | a Lawlor, B.4 aut |
700 | 1 | a Kennelly, S. P.4 aut |
700 | 1 | a Segurado, R.4 aut |
700 | 1 | a Kennelly, S.4 aut |
700 | 1 | a Rikkert, Mgmo4 aut |
700 | 1 | a Howard, R.4 aut |
700 | 1 | a Pasquier, F.4 aut |
700 | 1 | a Börjesson-Hanson, Anne,d 1959u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xborja |
700 | 1 | a Tsolaki, M.4 aut |
700 | 1 | a Lucca, U.4 aut |
700 | 1 | a Molloy, D. W.4 aut |
700 | 1 | a Coen, R.4 aut |
700 | 1 | a Riepe, M. W.4 aut |
700 | 1 | a Kalman, J.4 aut |
700 | 1 | a Kenny, R. A.4 aut |
700 | 1 | a Cregg, F.4 aut |
700 | 1 | a O'Dwyer, S.4 aut |
700 | 1 | a Walsh, C.4 aut |
700 | 1 | a Adams, J.4 aut |
700 | 1 | a Banzi, R.4 aut |
700 | 1 | a Breuilh, L.4 aut |
700 | 1 | a Daly, L.4 aut |
700 | 1 | a Hendrix, S.4 aut |
700 | 1 | a Aisen, P.4 aut |
700 | 1 | a Gaynor, S.4 aut |
700 | 1 | a Sheikhi, A.4 aut |
700 | 1 | a Taekema, D. G.4 aut |
700 | 1 | a Verhey, F. R.4 aut |
700 | 1 | a Nemni, R.4 aut |
700 | 1 | a Nobili, F.4 aut |
700 | 1 | a Franceschi, M.4 aut |
700 | 1 | a Frisoni, G.4 aut |
700 | 1 | a Zanetti, O.4 aut |
700 | 1 | a Konsta, A.4 aut |
700 | 1 | a Anastasios, O.4 aut |
700 | 1 | a Nenopoulou, S.4 aut |
700 | 1 | a Tsolaki-Tagaraki, F.4 aut |
700 | 1 | a Pakaski, M.4 aut |
700 | 1 | a Dereeper, O.4 aut |
700 | 1 | a de la Sayette, V.4 aut |
700 | 1 | a Senechal, O.4 aut |
700 | 1 | a Lavenu, I.4 aut |
700 | 1 | a Devendeville, A.4 aut |
700 | 1 | a Calais, G.4 aut |
700 | 1 | a Crawford, F.4 aut |
700 | 1 | a Mullan, M.4 aut |
700 | 1 | a Aalten, P.4 aut |
700 | 1 | a Berglund, M. A.4 aut |
700 | 1 | a Claassen, J. A.4 aut |
700 | 1 | a De Heus, R. A.4 aut |
700 | 1 | a De Jong, D. L. K.4 aut |
700 | 1 | a Godefroy, O.4 aut |
700 | 1 | a Hutchinson, S.4 aut |
700 | 1 | a Ioannou, A.4 aut |
700 | 1 | a Jonsson, Michael,d 1955u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xjonmi |
700 | 1 | a Kent, A.4 aut |
700 | 1 | a Kern, Jürgenu Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xkerju |
700 | 1 | a Nemtsas, P.4 aut |
700 | 1 | a Panidou, M. K.4 aut |
700 | 1 | a Abdullah, L.4 aut |
700 | 1 | a Paris, D.4 aut |
700 | 1 | a Santoso, A. M.4 aut |
700 | 1 | a van Spijker, G. J.4 aut |
700 | 1 | a Spiliotou, M.4 aut |
700 | 1 | a Thomoglou, G.4 aut |
700 | 1 | a Wallin, Anders,d 1950u Gothenburg University,Göteborgs universitet,Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi,Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry4 aut0 (Swepub:gu)xwaand |
710 | 2 | a Göteborgs universitetb Institutionen för neurovetenskap och fysiologi, sektionen för psykiatri och neurokemi4 org |
773 | 0 | t Journal of the American Medical Directors Associationd : Elsevier BVg 21:2, s. 194-200q 21:2<194-200x 1525-8610 |
856 | 4 8 | u https://gup.ub.gu.se/publication/290104 |
856 | 4 8 | u https://doi.org/10.1016/j.jamda.2019.08.006 |
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
Kopiera och spara länken för att återkomma till aktuell vy